By Tony Winterburn • Published: 27 May 2020 • 8:08
Regulators have approved Britain’s first medicine to treat coronavirus – a drug that was originally intended for use on Ebola victims. Clinical trials suggest that Remdesivir can shorten recovery time for Covid-19 sufferers by an average of four days, from 15 to 11.
A standard formal licence approval would normally take months but the Medicines and Healthcare products Regulatory Agency said the anti-viral drug can be prescribed before this is complete.
Hospital doctors are allowed to give Remdesivir to Covid-19 patients aged over 12, while clinical trials with the manufacturer Gilead Sciences continue. Health secretary Matt Hancock said we are “leading the world in clinical trials”, adding: “We will be prioritising the use of this treatment where it will find the greatest benefit.”
The move boosts efforts to find an effective treatment and improve NHS capacity to cope with a potential second wave of the disease.
Share this story
Subscribe to our Euro Weekly News alerts to get the latest stories into your inbox!
By signing up, you will create a Euro Weekly News account if you don't already have one. Review our Privacy Policy for more information about our privacy practices.
Share your story with us by emailing newsdesk@euroweeklynews.com, by calling +34 951 38 61 61 or by messaging our Facebook page www.facebook.com/EuroWeeklyNews
By signing up, you will create a Euro Weekly News account if you don’t already have one. Review our Privacy Policy for more information about our privacy practices.
Download our media pack in either English or Spanish.